Table 1. Summary of included studies
First author [ref.]Study nameStudy designStudy locationInterventionComparator
Konstan [15]EAGER trialRCT, open-label, non-inferiority trial (n=533) Duration: 24 weeks127 centres in 15 countries (including North America, Europe, Australia, Israel and Latin America)Tobramycin dry powder T-326 Inhaler, 112 mg twice daily; 28 days on followed by 28 days off treatmentTobramycin solution PARI LC Plus jet nebuliser, 300 mg/5 mL twice daily; 28 days on followed by 28 days off treatment
Konstan [13]
Novartis Pharmaceuticals [16]
European Medicines Agency [18]
Forest Laboratories Ltd [17]COLO/DPI/02/06RCT, open-label, non-inferiority trial (n=380) Duration: 24 weeks66 centres in European Union countries, and Russia and the UkraineColistimethate sodium dry powder Turbospin device, 125 mg twice daily; continuous treatmentTobramycin solution PARI LC Plus jet nebuliser, 300 mg/5 mL twice daily; 28 days on followed by 28 days off treatment
European Medicines Agency [1]
Forest Laboratories Ltd [17]COLO/DPI/02/05RCT, open-label with crossover (n=16) Duration: 8 weeks3 centres in the UKColistimethate sodium dry powder Turbospin device, 125 mg twice daily; continuous treatmentColistimethate sodium solution (device not reported), 2 MU twice daily; continuous treatment

  • RCT: randomised controlled trial.